Advanced search    

Search: authors:"Adam Brufsky"

14 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis

. Data curation: Xia Jiang, Richard Neapolitan. Formal analysis: Xia Jiang, Richard Neapolitan. Funding acquisition: Xia Jiang, Richard Neapolitan. Investigation: Xia Jiang, Alan Wells, Adam Brufsky ... Brufsky, Richard Neapolitan. Writing ? original draft: Xia Jiang, Richard Neapolitan. Writing ? review & editing: Xia Jiang, Alan Wells, Adam Brufsky, Richard Neapolitan. 17 / 18 1. http://www.nih.gov

Alcohol consumption and breast tumor gene expression

Alcohol consumption is an established risk factor for breast cancer and the association generally appears stronger among estrogen receptor (ER)-positive tumors. However, the biological mechanisms underlying this association are not completely understood. We analyzed messenger RNA (mRNA) microarray data from both invasive breast tumors (N = 602) and tumor-adjacent normal tissues...

Decreased risk of breast cancer associated with oral bisphosphonate therapy

Decreased risk of breast cancer associated with oral bisphosphonate therapy Aju Mathew,1 Adam Brufsky,21Department of Internal Medicine, University of Pittsburgh Medical Center, 2Division of

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Yardley et al. Trials Erratum to: 'Phase II/III weekly nab- Denise A. Yardley 2 Adam Brufsky 1 Robert E. Coleman 0 Pierfranco F. Conte 6 Javier Cortes 5 Stefan Glück 4 Jean-Mark A. Nabholtz 3 Joyce

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Background Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median progression-free survival of 4.6 months. nab-paclitaxel-based regimens (with gemcitabine or carboplatin ± bevacizumab) also demonstrated efficacy and...

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

Improvements in screening and adjuvant therapy for breast cancer are associated with decreased recurrence, which may have the effect of increasing the proportion of patients presenting with first-line de novo versus recurrent metastatic breast cancer (MBC). Here, we describe and compare patients with de novo versus recurrent human epidermal growth factor 2 (HER2)-positive MBC...

Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions

We report a case of a female with stage I infiltrating ductal carcinoma who received adjuvant therapy including trastuzumab. One year later she developed lytic lesions and was retreated with trastuzumab that was held after she developed symptomatic heart failure. Lytic lesions were attributed to relapse of breast cancer, and cardiac failure attributed to prior trastuzumab therapy...

Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions

We report a case of a female with stage I infiltrating ductal carcinoma who received adjuvant therapy including trastuzumab. One year later she developed lytic lesions and was retreated with trastuzumab that was held after she developed symptomatic heart failure. Lytic lesions were attributed to relapse of breast cancer, and cardiac failure attributed to prior trastuzumab therapy...

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer

Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishing

Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer

Introduction Breast Cancer Index (BCI) combines two independent biomarkers, HOXB13:IL17BR (H:I) and the 5-gene molecular grade index (MGI), that assess estrogen-mediated signalling and tumor grade, respectively. BCI stratifies early-stage estrogen-receptor positive (ER+), lymph-node negative (LN-) breast cancer patients into three risk groups and provides a continuous assessment...

Transcatheter Arterial Chemoembolization Is a Feasible Palliative Locoregional Therapy for Breast Cancer Liver Metastases

Buck,3 Jennifer Steel,1,4 Adam Brufsky,5 Roberta Gillespie,1 Allan Tsung,1 James W. Marsh,1 David A. Geller,1 and T. Clark Gamblin1,2,6 1Division of Transplantation, Department of Surgery, University of

CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer

Background The cell surface proteoglycan, chondroitin sulfate proteoglycan 4 (CSPG4), is a potential target for monoclonal antibody (mAb)–based immunotherapy for many types of cancer. The lack of effective therapy for triple-negative breast cancer (TNBC) prompted us to examine whether CSPG4 is expressed in TNBC and can be targeted with CSPG4-specific mAb.